Oncology Division
Alphabetical list (active faculty):   
Geoffrey L. Uy

Geoffrey L. Uy, MD


Department of Medicine

Oncology Division

Bone Marrow Transplantation & Leukemia

Clinical Interests

  • Stem-cell transplantation
  • Leukemia


  • 314-454-8304 (office)
  • 314-454-7551 (fax)
  • Division of Oncology
    Mail Stop 8007-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid Campus Center (office)


My research is focused on the development of new agents and treatment approaches for patients with myelodysplastic syndromes and acute leukemias. I currently serve as Medical Director for Clinical Research within the Division of Oncology and serve as the institutional principal investigator for industry and cooperative group sponsored studies for acute leukemias.

My primary research focus is on modulating tumor microenvironment interactions to improve therapy for acute leukemia. In preclinical models, disrupting key molecules such as CXCR4 and VLA-4 which mediate tumor microenvironment interactions increase the sensitivity of tumor cells to chemotherapy and have translated these studies into clinical trials. I am leading an investigator initiated study of BL8040 in combination with chemotherapy for patients with relapsed acute lymphoblastic leukemia. I am also currently leading the Alliance for Clinical Trials in Oncology study for older adults with de novo AML which will test an E-selectin antagonist, GMI-1271, in combination with conventional daunorubicin plus cytarabine chemotherapy.

Finally, I am also interested in the use of next generation sequencing technologies to measure disease response in myelodsysplastic syndromes and acute myeloid leukemia. We have demonstrated that can identify and track malignant clones during therapy with hypomethylating agents and may be an alternative measure of antitumor activity to supplement traditional response criteria which are based primarily on bone marrow morphology. These next generation sequencing approaches are being tested in the context of larger randomized studies being conducted in AML.